Industry Rating - The industry investment rating is maintained as "Outperform" [1] Core Views - The domestic demand for the research service sector is recovering, supported by national policies and increased market activity in innovative drugs, leading to stable revenue and profit growth [2][6] - The overseas business environment is showing steady recovery, with domestic companies making significant progress in international markets, enhancing their profit margins [3][19] - The overall performance of the research service sector is improving, with a notable increase in both domestic and overseas business contributions [6][41] Summary by Sections Financial Performance - For the first three quarters of 2025, the overall revenue of the research service sector increased by 6.61% year-on-year, with net profit rising by 13.30% and non-recurring net profit up by 20.89% [5][6] - In Q3 2025 alone, the sector's revenue grew by 8.53% year-on-year, with net profit increasing by 17.97% and non-recurring net profit by 36.37% [6] - The gross profit margin for the sector was 49.95%, reflecting a 1.64 percentage point increase year-on-year, attributed to improved product quality and effective cost control [6] Market Trends - The demand for innovative drug research is driving growth in the sector, with a significant increase in the number of projects and investments in high-value services [2][14] - The trend of domestic companies replacing imported products is gaining momentum, with leading firms expected to capture a larger market share [2][7] Company Recommendations - Companies to watch include Haoyuan Pharmaceutical, Baiao Saitou-H, Naimi Technology, Aopumai, Yaokang Biological, and Saifen Technology, which are likely to benefit from improved industry demand [4] - New business opportunities are emerging for Haoyuan Pharmaceutical and Baiao Saitou-H, particularly in ADC CDMO services [4][27] Segment Performance - The research service sector consists of 18 listed companies, with stable growth across various segments, including model animals, biological reagents, and chromatography materials [6][7] - Companies like Naimi Technology and Yaokang Biological are experiencing significant growth in their respective fields, driven by strong domestic and international demand [30][36]

Core Viewpoint - New materials are a key development direction for China's chemical industry, driven by new industrial demands, policy initiatives, and technological advancements in various sectors such as humanoid robots, AI, and sustainable aviation fuel [2][8]. Group 1: New Materials Development - The main focus for new materials in the second half of 2025 includes industrial new demands, such as those from humanoid robots requiring specific chemical materials like PEEK and high-strength PE, as well as policy-driven demands like bio-jet fuel [2][8]. - The development of synthetic biology, COC materials, and other high-value products is also noteworthy, alongside the progress in domestic alternatives to U.S. products post-tariff [2][8]. Group 2: Humanoid Robots - Humanoid robots are gaining attention due to their potential applications across various fields, including industrial, medical, and entertainment sectors, with significant investments from major tech companies [10][12]. - The focus on lightweight materials in humanoid robots is crucial, as seen in Tesla's Optimus Gen-2, which has reduced weight by 10 kg, enhancing energy efficiency and operational flexibility [12][13]. Group 3: Sustainable Aviation Fuel (SAF) - The global aviation fuel consumption is approximately 328 million tons, with SAF recognized as a viable solution to reduce carbon emissions by up to 85% compared to traditional fuels [17][20]. - The implementation of the CORSIA mechanism starting in 2025 is expected to drive rapid growth in SAF demand, with various countries setting ambitious blending targets [20][21]. Group 4: Electronic Specialty Gases - The electronic specialty gas market is projected to reach $6.023 billion by 2025, with a CAGR of 6.39% from 2022 to 2025, driven by the semiconductor industry's recovery and domestic substitution [27][29]. - The semiconductor industry's growth is expected to boost the demand for electronic specialty gases, with significant investments in advanced logic and storage applications [27][29]. Group 5: OLED Market - The OLED market is expanding rapidly, with mobile devices increasingly adopting OLED screens, which accounted for 57% of smartphone displays in 2021 [30][31]. - The penetration of OLED technology into tablets and automotive displays is anticipated to further drive demand, supported by major manufacturers' investments in production capacity [34][31]. Group 6: PCB Resin and Upgrades - The demand for high-end PCB resins is increasing due to the upgrade of computing power and servers, with a focus on domestic substitution in the supply chain [35][46]. - The transition to high-speed data transmission requires advanced resin materials, creating opportunities for domestic manufacturers to meet the growing demand [40][46]. Group 7: Synthetic Biology - The global synthetic biology market is expected to grow from $5.3 billion in 2019 to $18.9 billion by 2024, with a CAGR of 29% [59]. - Advances in gene sequencing and editing technologies are driving the rapid development of synthetic biology, with significant implications for various industries [59].

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 股东大会有关情况 证券代码：688690 证券简称：纳微科技 公告编号：2025-038 苏州纳微科技股份有限公司 关于2025年第一次临时股东大会 取消部分议案的公告 近日，公司在对候选人关联关系进行补充核查时发现，按照公司相关管理制 1、 股东大会的类型和届次： 2025年第一次临时股东大会 2、 股东大会召开日期：2025 年 11 月 17 日 3、 股东大会股权登记日： | 股份类别 | 股票代码 | 股票简称 | 股权登记日 | | --- | --- | --- | --- | | A 股 | 688690 | 纳微科技 | 2025/11/11 | 二、 取消议案的情况说明 1、 取消议案名称 | 序号 | 议案名称 | | --- | --- | | 3 | 关于补选董事的议案 | 2、 取消议案原因 公司于 2025 年 10 月 27 日召开第三届董事会第九次会议，审议通过《关于 补选董事的议案》，同意提名刘军博士为公司第三届董事会董事候选人。 度， ...

苏州纳微科技股份有限公司 2025 年第一次临时股东大会会议资料 证券代码：688690 证券简称：纳微科技 苏州纳微科技股份有限公司 2025年第一次临时股东大会 会议资料 二〇二五年十一月 1 苏州纳微科技股份有限公司 2025 年第一次临时股东大会会议资料 会议资料目录 | 2025 | 年第一次临时股东大会会议须知 3 | | | --- | --- | --- | | 2025 | 年第一次临时股东大会会议议程 5 | | | | 一、会议时间、地点及投票方式 | 5 | | | 二、会议议程 | 5 | | 2025 | 年第一次临时股东大会会议议案 7 | | | | 议案一：关于取消监事会、修订《公司章程》并办理工商变更登记的议案 | 7 | | | 议案二：关于修订部分公司治理制度的议案 | 8 | | | 议案三：关于调整部分董事 2025 年度薪酬方案的议案 | 9 | 七、主持人可安排公司董事、监事、高级管理人员回答股东（或股东代理人）所提问 题。对于可能将泄露公司商业秘密及/或内幕信息，损害公司、股东共同利益的提问，主持 人或其指定的有关人员有权拒绝回答。 2 苏州纳微科技股份有限公 ...

Group 1: Market Overview - The recent volatility in the US stock market has raised concerns about a potential new round of market correction, with the Nasdaq dropping by 2% on November 4 and significant declines in Japanese and Korean markets [2][11] - The tightening of dollar liquidity due to the US government shutdown has been identified as a catalyst for increased market fluctuations, with the Treasury General Account (TGA) rising by $200 billion since October [11] Group 2: North Exchange Market Analysis - The North Exchange's Q3 report shows a revenue growth of 5.3% year-on-year, but net profit decreased by 5.0%, indicating ongoing profitability challenges [10][12] - The return on equity (ROE) improved slightly to 6.1%, with asset turnover at 62.0% and net profit margin at 5.6% [10][12] Group 3: Investment Opportunities in Specific Sectors - The industrial automation sector is highlighted as a growth area, with the company achieving market share increases in low-voltage frequency converters and servo systems from 1.80% and 0.55% in 2019 to 3.02% and 2.30% by 2024 [19] - The human-shaped robot industry is also noted for its potential, with the company leveraging its automation technology to reduce R&D cycles and costs [19][20] Group 4: Pharmaceutical Sector Performance - The pharmaceutical sector reported a total revenue of 18,064 billion yuan in the first three quarters of 2025, with a slight year-on-year decline of 1.9% [21][24] - The innovative drug segment showed a significant revenue increase of 36% in Q3, indicating strong growth potential [21][24]

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, particularly recommending a focus on innovative drugs and sectors with improving performance such as medical devices and CXO [1][10]. Core Insights - The pharmaceutical sector in Q3 2025 showed signs of recovery with a year-on-year revenue growth of 0.6% in Q3, marking the first positive growth in four quarters [1][10]. - Innovative drugs demonstrated a remarkable revenue growth of 36% in Q3 2025, with a turnaround in net profit from a loss of 500 million to a profit of 1.5 billion [10]. - The CXO sector also showed strong performance with a revenue growth of 10.9% and a net profit increase of 47.7% year-on-year, indicating a trend reversal [10]. Summary by Sections Q3 2025 Performance - The A-share pharmaceutical sector, excluding certain companies, achieved total revenue of 1,806.4 billion with a year-on-year decline of 1.9% and a net profit of 139.2 billion, down 5.1% year-on-year [2][11]. - In Q3 2025, total revenue reached 600.4 billion, reflecting a year-on-year increase of 0.6% but a quarter-on-quarter decrease of 0.4% [2][11]. Profitability and Margins - The gross profit for the pharmaceutical sector in Q3 2025 was 189.1 billion, with a gross margin of 31.5%, slightly down from the previous year [5][8]. - The overall net profit margin for Q3 2025 was 6.8%, showing a slight decline compared to the previous year [8]. Cash Flow - The sector reported a net cash inflow from operating activities of 59.1 billion in Q3 2025, representing a year-on-year growth of 17.9% [7][13]. Subsector Performance - The innovative drug sector's revenue growth of 36% and the CXO sector's revenue growth of 10.9% highlight the strong recovery and growth potential within these subsectors [10][11]. - The report emphasizes the importance of focusing on companies such as 恒瑞医药, 长春高新, and 药明康德, which are expected to perform well in the current market environment [1][10].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, indicating a positive outlook for the sector compared to the overall market performance [22]. Core Insights - The pharmaceutical sector has shown signs of recovery, with the first positive year-on-year revenue growth in four quarters, driven by strong performances in the innovative drug and CXO segments [2][11]. - Innovative drugs achieved a remarkable 36% revenue growth in Q3 2025, transitioning from a loss of 500 million to a profit of 1.5 billion, highlighting the sector's high growth potential [11]. - The CXO segment has also shown a significant turnaround, with a year-on-year revenue growth of 10.9% and a net profit increase of 47.7%, expected to maintain mid-to-high growth in the coming year [11]. Summary by Sections Industry Performance - In the first three quarters of 2025, the A-share pharmaceutical and biotechnology sector, excluding certain companies, generated total revenue of 1,806.4 billion yuan, a year-on-year decrease of 1.9%, and a net profit of 139.2 billion yuan, down 5.1% [2][3]. - For Q3 2025, total revenue reached 600.4 billion yuan, reflecting a year-on-year increase of 0.6% but a quarter-on-quarter decrease of 0.4% [2][3]. Profitability Metrics - The gross profit for Q3 2025 was 189.1 billion yuan, with a gross margin of 31.5%, showing a slight decline compared to previous periods [5][8]. - The overall net profit margin for the sector in Q3 2025 was 6.8%, down 0.05 percentage points year-on-year and 1.47 percentage points quarter-on-quarter [8]. Cash Flow Analysis - The sector reported a net cash inflow from operating activities of 59.1 billion yuan in Q3 2025, marking a year-on-year increase of 17.9% and achieving positive growth for two consecutive quarters [7][14]. Subsector Performance - The report highlights the strong performance of the innovative drug and CXO subsectors, with innovative drugs showing a significant recovery and CXO experiencing a positive trend reversal [11][12].

Core Viewpoint - The performance of the Zhongzheng 1000 ETF Enhanced (561280) has shown a decline of 1.40% as of the midday close on November 4, with a trading volume of 2.7092 million yuan [1] Group 1: Fund Performance - The Zhongzheng 1000 ETF Enhanced (561280) has a performance benchmark based on the Zhongzheng 1000 Index return [1] - Since its establishment on August 31, 2023, the fund has achieved a return of 50.30% [1] - The fund's return over the past month has been -0.40% [1] Group 2: Major Holdings - Major stocks in the fund include: - Boqian New Materials, down 3.15% - Haoyuan Pharmaceutical, down 0.64% - Yingjixin, down 2.04% - Caixun Co., down 0.18% - Jinma Amusement, up 0.85% - Panjiang Co., down 0.39% - Jindawei, down 0.84% - Yiyuan Communication, down 2.75% - Minxin Co., down 1.60% - Nami Technology, down 1.97% [1]

Core Viewpoint - The recent lawsuit filed by Liang Jun, former CTO of Cambricon, against the company for 4.287 billion yuan has highlighted the growing issue of equity incentives in the tech sector, raising concerns about the complexities and disputes surrounding them [2][3]. Group 1: Industry Context - The tech and internet sectors are identified as the primary areas for equity incentive disputes, with over 90% of related lawsuits occurring in these fields from 2019 to March 2023 [3]. - The significant valuation discrepancies before and after a company's IPO contribute to the high stakes involved in equity disputes, as the value of shares can increase dramatically post-listing [2]. Group 2: Legal and Contractual Considerations - Companies must meticulously design contract terms for equity incentives, clearly defining potential risk points and conditions under which equity may be affected, such as reasons for employee departure [4]. - Employees should thoroughly review contract terms and not sign blindly, paying particular attention to clauses regarding exit, repurchase, and expiration [4]. Group 3: Professional Guidance - Companies are encouraged to seek professional legal and tax advice when establishing equity incentive plans to ensure clarity and compliance with regulations, as the complexity of these plans often exceeds the capabilities of standard HR and legal departments [4][5].

Core Viewpoint - The performance of the Zhongzheng 1000 ETF Enhanced (561280) shows a positive trend with a year-to-date return of 52.00% since its establishment on August 31, 2023, indicating strong market interest and potential investment opportunities [1] Group 1: Fund Performance - The Zhongzheng 1000 ETF Enhanced opened at 1.514 yuan, reflecting a 0.46% increase [1] - The fund's performance benchmark is the Zhongzheng 1000 Index return [1] - The fund manager is Industrial Bank of China Credit Fund Management Co., Ltd., with Liu Zihao as the fund manager [1] Group 2: Stock Performance - Key stocks in the fund include: - Boqian New Materials: down 0.17% - Haoyuan Pharmaceutical: up 0.36% - Yingjixin: down 0.31% - Caixun Co.: down 0.28% - Jinma Amusement: up 0.13% - Panjiang Co.: down 0.38% - Jindawei: up 0.20% - Yiyuan Communication: up 0.02% - Minxin Co.: down 5.44% - Nami Technology: down 0.06% [1] Group 3: Recent Returns - The fund has achieved a return of 1.93% over the past month [1]